Video

Dr. Bruix on the Phase III RESORCE Trial in HCC

Author(s):

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

The trial assessed patients with HCC who had previously progressed on sorafenib. Patients were randomized 2:1 to receive regorafenib at 160 mg per day or placebo on weeks 1-3 of each 4-week cycle until progression, death, or unacceptable toxicity.

Overall survival (OS), which was the study's primary endpoint, was significantly improved, with a hazard ratio of 0.63, explains Bruix. The results demonstrated that regorafenib was active, efficacious, and provided clinically meaningful improvement in OS, says Bruix.